

December 12, 2018



Orgenesis CEO Vered Caplan to Present at William Blair's Biotech Focus Day Series: Cell and Gene Therapy Manufacturing

GERMANTOWN, Md., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider today announced that Vered Caplan, CEO of Orgenesis, will participate in William Blair's Biotech Focus Day Series: Cell and Gene Therapy Manufacturing, which will combine experts and leading companies involved in the rapid expansion of potentially curative therapies and the logistical hurdles in their development.

Ms. Caplan will provide a morning presentation entitled, "Thinking inside the box: centralized vs decentralized manufacturing." Ms. Caplan will also participate in a midday panel discussion of current issues in manufacturing including scale up, automation, release specifications, and commercial logistics. The panel discussion will feature senior executives of leading companies in the cell and gene therapy and manufacturing sectors, including LogicBio Therapeutics, Rocket Pharmaceuticals, and Celyad. The panel will be moderated by Philip Wills, Ph.D., Chief Commercial Officer of Paragon Bioservices.

About Orgenesis

Orgenesis is vertically integrated service and research company in the regenerative medicine industry with a focus on cell and gene therapy development and manufacturing. The Company operates through two platforms including (i) a Cell Therapy ("CT") development platform and (ii) a Contract Development and Manufacturing Organization ("CDMO") platform. Through the CT development platform, Orgenesis is focused on the development of proprietary cell therapies, including an autologous trans-differentiation technology and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharma companies and research and healthcare institutes. Through the CDMO platform, Orgenesis is focused on manufacturing and development services for other biopharma companies. The CDMO platform operates through Masthercell Global, which currently consists of MaSTherCell in Belgium, Atvio in Israel and subsidiaries in South Korea and in the United States, each having unique know-how and expertise for manufacturing in a multitude of cell types. These capabilities offered to third-parties are also utilized for internal development projects, with the goal of allowing Orgenesis to bring new products to patients faster and in a cost-effective way. Additional information is available at: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-

looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the success of our reorganized CDMO operations, the success of our partnership with Great Point Partners, our ability to achieve and maintain overall profitability, the sufficiency of working capital to realize our business plans, the development of our transdifferentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended November 30, 2017, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact for Orgenesis:

David Waldman

Crescendo Communications, LLC

Tel: 212-671-1021

Orgs@crescendo-ir.com



Source: Orgenesis Inc.